Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Its introduction should be guided by a thorough assessment of patient history, lifestyle factors, and clinical goals, alongside structured monitoring to ensure safety and efficacy
Lara has treated thousands of patients with complex metabolic conditions over three decades of practice
Due to patent protection, earlier it was marketed globally only by the innovator company under brand names like Ozempic, Wegovy, and Rybelsus, which made therapy expensive and limited its accessibility for many patients in India
In terms of cardiovascular and renal outcomes, DPP-4 inhibitors have not demonstrated benefits in comparison with placebo and have been proven to be inferior to GLP-1 RAs and SGLT2 inhibitors
/assets/images/provider/photos/2775905.jpeg)
